Home>Topics>Stocks>Auxilium Pharmaceuticals

Auxilium Pharmaceuticals AUXL

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Joint Ad Comm meeting Wednesday to discuss TRT


      Mon, 15 Sep 2014

      testosterone replacement therapy (TRT) and the potential for adverse cardiovascular outcomes associated with TRT. Briefing docs Related tickers: ( ABBV +0.1% ) ( LLY -0.1% ) ( AUXL -2.9% ) ( TEVA -1.4% ) Post your comment!

    2. From Barron’s, September 15, 2014 (Part 2)


      Sat, 13 Sep 2014

      department stores – M ; discount – BURL ; avoid women’s apparel and teen retailers]. Bearish stories: Auxilium Pharma [ AUXL ; money losing company is doing a tax-inversion by buying Canadian QLTI ; pg 18]. Pg 30: New Constructs website tracks and

    3. Auxilium Pharma +3% on news of corporate restructuring


      Tue, 9 Sep 2014

      Auxilium Pharma (NASDAQ: AUXL ) +3% AH after announcing a corporate ..... drive sustainable earnings growth." AUXL plans include a ~30% workforce reduction ..... least $75M/year in cost savings. AUXL expects to record restructuring related

    4. Antares: An Analysis Of FDA Briefing Documents For September 17th Advisory Committee Meeting On Testosterone Replacement Products


      Thu, 4 Sep 2014

      replacement products. Testosterone replacement gel products like AbbVie's (NYSE: ABBV ) Androgel and Auxilium's (NASDAQ: AUXL ) Testim became huge sellers in the last decade and there have been a number of new competitors, both gels and injectables

    5. Update: BioSpecifics Announces Positive XIAFLEX Data For Cellulite


      Wed, 27 Aug 2014

      in the appearance of cellulite, measured by the trial endpoints. BioSpecifics' strategic partner Auxilium Pharmaceuticals (NASDAQ: AUXL ) conducted the trial, the primary endpoint of which was an investigator and a patient score on the

    6. UPDATE 2-Auxilium drug effective against cellulite in mid-stage study


      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Auxilium Pharmaceuticals Inc said two doses of its drug to smoothen cellulite were statistically significant in a mid-stage study, sending its shares up nearly 8 percent.

    7. Auxilium reports trial results for cellulite product candidate


      Thu, 21 Aug 2014

      Auxilium Pharmaceuticals (NASDAQ: AUXL ) announces the results from a Phase 2a clinical trial evaluating the safety and efficacy of injections of collagenase clostridium

    8. Auxilium drug found effective against cellulite in mid-stage study


      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Auxilium Pharmaceuticals Inc said its experimental drug showed significant improvement in smoothing cellulite in a mid-stage study.

    9. 2nd Half Of 2014 Biotechnology Catalysts - Part 4


      Sun, 17 Aug 2014

      By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...

    10. Update: BioSpecifics Technologies Earnings


      Fri, 15 Aug 2014

      and controls patents and patent applications for XIAFLEX and is entitled to get royalties until 2028 from Auxilium (NASDAQ: AUXL ) for Dupuytren's Contracture, Peyronie's Disease, Frozen Shoulder and Cellulite. Thomas L. Wegman, President of BioSpecifics

    « Prev1234Next »
    Content Partners